CClinicalTrials.gg
Status unknownNCT01746823Updated Mar 6, 2014

Identification and Validation of Functional Biomarkers for Keratoconus

An observational study in Keratoconus, sponsored by Narayana Nethralaya. Status unknown at 1 site in India. Open to participants aged 10 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-06.

Sponsored by Narayana Nethralaya · Observational

The sponsor has not verified this record recently (last verified Dec 2012), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
10 Years to 80 Years
Sex
All
01

Study summary

There is currently no medication for containing KC, nor any adequate biomarkers to predict the disease. Furthermore, there is considerable confusion in the field regarding the pathophysiology of the disease and involvement of inflammation. To that end, this study is designed to address some of these questions by determining the proteomic profiles of KC patients with different clinical grades. This relatively large cohort study is expected to yield significant information regarding the molecules that are deregulated during progression of KC and may provide a framework to assign diagnostic biomarkers and therapeutic intervention points.

Read the detailed description

The screening of keratoconus involves keratoconus related clinical signs like retinoscopy scissors reflex, Munson sign, stromal thinning, Vogt's striae, and Fleischer's ring, but corneal topography is the most useful method in the diagnosis of keratoconus, especially in the absence of clinical signs.

Several devices are currently available for detecting early keratoconus by measuring anterior and posterior corneal topography and elevation(Mihaltz et al. 2009; Ishii et al. 2012). Corneal topographic and tomographic techniques which generate color-coded maps and topographic indices, are the most sensitive devices for confirming the diagnosis of keratoconus(Rabinowitz 1998; Rao et al. 2002) were used for diagnosis in this study. In addition, videokeratography has been shown to identify Forme fruste keratoconus (FFKC) in the absence of clinical signs of keratoconus. Videokeratographic indices such as the Klyce/Maeda criteria, the Rabinowitz criteria, and others have been developed to quantitatively analyze videokeratography and screen for keratoconus(Rao et al. 2002). These indices have been shown to identify keratoconus with a high degree of sensitivity and specificity. The Orbscan II is a three-dimensional slit-scan topography system for analysis of the corneal surfaces and anterior chamber and has been used on all patients in the study. It uses calibrated video and a scanning slit beam to measure x, y, and z locations of several thousand points. These points are used to construct topographic maps(Rao et al. 2002). The Pentacam (Oculus Inc) is a corneal tomographer technology which generates data on topograophy and elevation of anterior and posterior using a rotating Scheimpflug camera which has also been used on all subjects enrolled in this study. Various diagnostic parameters are available for keratoconus diagnosis depending on what mode of topography is being used. Maeda and Klyce designed a system to detect keratoconus. The system, which is based on linear discriminant analysis and a binary decision tree, identifies the map as representing keratoconus or nonkeratoconus and, based on a value from the discriminant analysis (the KPI), assigns the map an index expressed as a percentage that suggests the severity of keratoconus. At this time, however, Keratoconus Severity Index (KSI) and the Amsler-Krumeich classification are the most popular methods for grading keratoconus severity(Mihaltz et al. 2009; Ishii et al. 2012). KSI is based on indices estimated by a curvature map using Placido disk-based corneal topography, and Amsler-Krumeich classification defines the stage of keratoconus using biomicroscopy, mean central keratometry reading, spherical and cylindrical refraction change, and corneal thickness(Mihaltz et al. 2009; Ishii et al. 2012). This is the index that has been used for the final gradation of keratoconus stages of all subjects in this study.

02

Conditions studied

  • Keratoconus

Browse trials for

Keywords

  • Keratoconus
  • Proteomics
03

In context

Keratoconus

307 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's planned enrollment of 200 is above the median of 130 across 94 observational studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

Narayana Nethralaya is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients detected with corneal thinning by keratometry at a tertiary level hospital

Inclusion criteria

  • Evidence of corneal thinning by any type of keratometry

Exclusion criteria

Exclusion Criteria:

  • Corneal inflammation without evidence of ectasia
  • Retinal disorder subjects excluded
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Controls, Keratoconus

    Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A

    Drug: Cyclosporins

Interventions

  • DrugCyclosporins

    Also known as: Restasis

06

What researchers measure

Primary outcomes

  1. Keratoconus grade specific biomarker identification

    Time frame: 1 year

Secondary outcomes

  1. Onlabel use of anti-allergic topical treatment for inhibition of specific biomarkers to modify keratoconus disease progression

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Narayana Nethralaya
    Bangalore, Karnataka 560010, India
    • Rohit Shetty, DNB, FRCS · Contact · drrohitshetty@yahoo.com · 91-9611102568
    • Rohit Shetty, MBBS, DNB, FRCS · Principal investigator
    Recruiting
08

References and documents

Publications

  • Gontier J, Fisch U. Schirmer's test: its normal values and clinical significance. ORL J Otorhinolaryngol Relat Spec. 1976;38(1):1-10. doi: 10.1159/000275252. PubMed 943747 ↗
  • Shetty R, Ghosh A, Lim RR, Subramani M, Mihir K, Reshma AR, Ranganath A, Nagaraj S, Nuijts RM, Beuerman R, Shetty R, Das D, Chaurasia SS, Sinha-Roy A, Ghosh A. Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. Invest Ophthalmol Vis Sci. 2015 Feb 3;56(2):738-50. doi: 10.1167/iovs.14-14831. PubMed 25648341 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01746823
Lead sponsor
Narayana Nethralaya
Collaborators
Singapore Eye Research Institute
Responsible party
Dr Rohit Shetty (Consultant, Cornea and Refractive Services, Narayana Nethralaya) — Principal investigator
First posted
Dec 11, 2012
Start date
Apr 2013
Primary completion
Dec 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Mar 6, 2014

Study contacts

Rohit Shetty, MBBS,DNB, FRCS
principal investigator · Narayana Nethralaya

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion